DDInter1055 DDInter927
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
Levofloxacin {u} (Compound) upregulates {v} (Gene) CPVL
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Levofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Levofloxacin {u} (Compound) downregulates {v} (Gene) TRIB3
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dysphagia
Levofloxacin (Compound) resembles Enoxacin (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound)
Levofloxacin (Compound) binds ABCB1 (Gene)
Levofloxacin (Compound) upregulates CPVL (Gene)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Levofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Levofloxacin (Compound) downregulates TRIB3 (Gene)
Levofloxacin (Compound) causes Dysphagia (Side Effect)